Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-01-2017 | Original Article

Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer

Authors: Mathieu Gauthé, Marion Richard-Molard, Juliette Fayard, Jean-Louis Alberini, Wulfran Cacheux, Astrid Lièvre

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 1/2017

Abstract

Purpose

The aim of this study was to confirm the prognostic value of metabolic tumour volume (MTV) at the primary site on initial work-up FDG PET/CT in patients with squamous cell carcinoma (SCC) of the anal canal.

Methods

Patients with a recent diagnosis of SCC of the anal canal without metastases undergoing PET/CT for initial work-up and treated with (chemo)radiotherapy were retrospectively reviewed. Computer-aided MTV and SUVmax were determined. Survival rates were estimated using the Kaplan-Meier method. Cox regression analysis was used to evaluate prognostic variables of progression-free survival and overall survival (OS).

Results

The study group comprised 75 patients who had an initial work-up PET/CT. Five patients (6.7 %) had stage I disease, 22 (29.3 %) stage II disease, 20 (26.7 %) stage IIIA disease, and 28 (37.3 %) stage IIIB disease. Median follow-up was 51 months (range 10 – 117 months). Global 4-year OS was 82.7 %, ranging from 100 % in patients with stage I disease to 75 % in patients with stage IIIB disease. MTV at the primary site was significantly and independently correlated with OS (p < 0.05), as patients with MTV less than 7 cm³ had a better prognosis. SUVmax was not correlated with survival parameters. Metabolic involvement of the inguinal lymph nodes was also correlated with a poor outcome in the univariate analysis (p < 0.05).

Conclusion

MTV at the primary site is a prognostic biomarker in anal canal cancer. Hypermetabolic inguinal lymph nodes also appear to be correlated with survival.

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Anal Cancer. Bethesda, MD: National Cancer Institute. 2016. http://seer.cancer.gov/statfacts/html/anus.html. Accessed 4 Aug 2016

Edge S, Byrd D, Compton CC, Fritz A, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 165–73.

Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson 3rd AB, Thomas Jr CR, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299:1914–21.CrossRefPubMed

Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson 3rd AB, Thomas Jr CR, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116:4007–13.

Bazan JG, Koong AC, Kapp DS, Quon A, Graves EE, Loo BW, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med. 2013;54:27–32.CrossRefPubMed

Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328–33.CrossRefPubMed

Dibble EH, Alvarez ACL, Truong M-T, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med. 2012;53:709–15.CrossRefPubMed

Schellenberg D, Quon A, Minn AY, Graves EE, Kunz P, Ford JM, et al. 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 2010;77:1420–5.CrossRefPubMed

Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS et al. Anal carcinoma. In: NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. 2016. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 4 Aug 2016.

10.

Deutsch E, Brunet R, Peiffert D, Salmon R, Siproudhis L, Touboul E. Cancer du canal anal. In: Thésaurus National de Cancérologie Digestive (TNCD). Société Nationale Française de Gastro-Entérologie. 2010. http://www.tncd.org/. Accessed 4 Aug 2016.

11.

Cotter SE, Grigsby PW, Siegel BA, Dehdashti F, Malyapa RS, Fleshman JW, et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys. 2006;65:720–5.CrossRefPubMed

12.

Day FL, Link E, Ngan S, Leong T, Moodie K, Lynch C, et al. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Br J Cancer. 2011;105:498–504.CrossRefPubMedPubMedCentral

13.

Ortholan C, Resbeut M, Hannoun-Levi J-M, Teissier E, Gerard J-P, Ronchin P, et al. Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study). Int J Radiat Oncol Biol Phys. 2012;82:1988–95.CrossRefPubMed

14.

Tomaszewski JM, Link E, Leong T, Heriot A, Vazquez M, Chander S, et al. Twenty-five-year experience with radical chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2012;83:552–8.CrossRefPubMed

15.

Zilli T, Betz M, Bieri S, Ris F, Roche B, Roth AD, et al. Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. Int J Radiat Oncol. 2013;87:60–6.CrossRef

16.

Gunderson LL, Winter KA, Ajani JA, Pedersen JE, Moughan J, Benson AB, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012;30:4344–51.CrossRefPubMedPubMedCentral

17.

Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14:2527–39.PubMed

18.

James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013;14:516–24.CrossRefPubMed

19.

Peiffert D, Giovannini M, Ducreux M, Michel P, François E, Lemanski C, et al. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2001;12:397–404.

20.

Peiffert D, Tournier-Rangeard L, Gérard J-P, Lemanski C, François E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012;30:1941–8.CrossRefPubMed

21.

Saboo SS, Zukotynski K, Shinagare AB, Krajewski KM, Ramaiya N. Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up. Abdom Imaging. 2012;38:728–35.CrossRef

22.

Vercellino L, Montravers F, de Parades V, Huchet V, Kerrou K, Bauer P, et al. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. Int J Colorectal Dis. 2010;26:201–10.CrossRef

23.

Schwarz JK, Siegel BA, Dehdashti F, Myerson RJ, Fleshman JW, Grigsby PW. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys. 2008;71:180–6.CrossRefPubMed

24.

Kidd EA, Dehdashti F, Siegel BA, Grigsby PW. Anal cancer maximum F-18 fluorodeoxyglucose uptake on positron emission tomography is correlated with prognosis. Radiother Oncol. 2010;95:288–91.CrossRefPubMed

25.

Mistrangelo M, Pelosi E, Bellò M, Ricardi U, Milanesi E, Cassoni P, et al. Role of positron emission tomography-computed tomography in the management of anal cancer. Int J Radiat Oncol. 2012;84:66–72.CrossRef

Title: Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer
Authors: Mathieu Gauthé
Marion Richard-Molard
Juliette Fayard
Jean-Louis Alberini
Wulfran Cacheux
Astrid Lièvre
Publication date: 01-01-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 1/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3475-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2017

How to scan who: the delicate balance between selecting the patient and selecting the imaging protocol

Do paraneoplastic changes in diffuse FDG organ uptake predict relapse? – Wait for confirmation study

[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches

The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma

Segmental 18F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy

Reply